Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120 Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...

Exavir Therapeutics Completes $4M Seed Financing from Key Investors NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...

Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9 Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...